Low Back Pain – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Low Back Pain – Pipeline Review, H1 2017’, provides an overview of the Low Back Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Low Back Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Low Back Pain

The report reviews pipeline therapeutics for Low Back Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Low Back Pain therapeutics and enlists all their major and minor projects

The report assesses Low Back Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Low Back Pain

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Low Back Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Low Back Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ache Laboratorios Farmaceuticos SA

Adynxx Inc

AnGes MG Inc

Array BioPharma Inc

Axsome Therapeutics Inc

Boehringer Ingelheim GmbH

Egalet Corp

Frontier Biotechnologies Co Ltd

Gador SA

Grunenthal GmbH

Hisamitsu Pharmaceutical Co Inc

Huons Co Ltd

Immune Pharmaceuticals Inc

KPI Therapeutics Inc

MD Biosciences GmbH

Mesoblast Ltd

Nektar Therapeutics

Orion Oyj

Pacira Pharmaceuticals Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Stayble Therapeutics AB

Sun Pharma Advanced Research Company Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Low Back Pain - Overview

Low Back Pain - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Low Back Pain - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Low Back Pain - Companies Involved in Therapeutics Development

Ache Laboratorios Farmaceuticos SA

Adynxx Inc

AnGes MG Inc

Array BioPharma Inc

Axsome Therapeutics Inc

Boehringer Ingelheim GmbH

Egalet Corp

Frontier Biotechnologies Co Ltd

Gador SA

Grunenthal GmbH

Hisamitsu Pharmaceutical Co Inc

Huons Co Ltd

Immune Pharmaceuticals Inc

KPI Therapeutics Inc

MD Biosciences GmbH

Mesoblast Ltd

Nektar Therapeutics

Orion Oyj

Pacira Pharmaceuticals Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Stayble Therapeutics AB

Sun Pharma Advanced Research Company Ltd

Low Back Pain - Drug Profiles

(acetaminophen + caffeine + diclofenac sodium + orphenadrine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(acetaminophen + tramadol hydrochloride) + eperisone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(loxoprofen + methocarbamol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-0101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-954 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AYX-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bupivacaine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cebranopadol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexmedetomidine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HP-3150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IG-8801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MD-22 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPC-06ID - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NKTR-181 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxycodone hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPARC-1401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STA-363 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tanezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

U-2902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zoledronic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Low Back Pain - Dormant Projects

Low Back Pain - Discontinued Products

Low Back Pain - Product Development Milestones

Featured News & Press Releases

Mar 24, 2017: AnGes: Investigational New Drug (IND) Application Submitted to the FDA

Mar 20, 2017: NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain

Mar 15, 2017: Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast’s Cell Therapy

Aug 01, 2016: MesoblastS Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science

Jul 25, 2016: Hisamitsu Pharmaceutical Announces the results of Phase II clinical study of HP-3150 in Japan for “Lower back pain” (an analgesic transdermal drug containing NSAIDs)

Jun 22, 2016: Frontier Biotech Reports Primary Endpoint Met in Phase 2 Trial of AB001 In Chronic Low Back Pain

Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms

Aug 28, 2015: Hisamitsu Pharmaceutical Announces commencement of the Phase II clinical study of HP-3150 in Japan for “Lower back pain” (an analgesic transdermal drug containing NSAIDs)

Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Low Back Pain, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Low Back Pain – Pipeline by Ache Laboratorios Farmaceuticos SA, H1 2017

Low Back Pain – Pipeline by Adynxx Inc, H1 2017

Low Back Pain – Pipeline by AnGes MG Inc, H1 2017

Low Back Pain – Pipeline by Array BioPharma Inc, H1 2017

Low Back Pain – Pipeline by Axsome Therapeutics Inc, H1 2017

Low Back Pain – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Low Back Pain – Pipeline by Egalet Corp, H1 2017

Low Back Pain – Pipeline by Frontier Biotechnologies Co Ltd, H1 2017

Low Back Pain – Pipeline by Gador SA, H1 2017

Low Back Pain – Pipeline by Grunenthal GmbH, H1 2017

Low Back Pain – Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017

Low Back Pain – Pipeline by Huons Co Ltd, H1 2017

Low Back Pain – Pipeline by Immune Pharmaceuticals Inc, H1 2017

Low Back Pain – Pipeline by KPI Therapeutics Inc, H1 2017

Low Back Pain – Pipeline by MD Biosciences GmbH, H1 2017

Low Back Pain – Pipeline by Mesoblast Ltd, H1 2017

Low Back Pain – Pipeline by Nektar Therapeutics, H1 2017

Low Back Pain – Pipeline by Orion Oyj, H1 2017

Low Back Pain – Pipeline by Pacira Pharmaceuticals Inc, H1 2017

Low Back Pain – Pipeline by Pfizer Inc, H1 2017

Low Back Pain – Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Low Back Pain – Pipeline by Stayble Therapeutics AB, H1 2017

Low Back Pain – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Low Back Pain – Dormant Projects, H1 2017

Low Back Pain – Dormant Projects, H1 2017 (Contd..1), H1 2017

Low Back Pain – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Low Back Pain, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports